PMID- 27092494
OWN - NLM
STAT- MEDLINE
DCOM- 20161216
LR  - 20181202
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 17
IP  - 4
DP  - 2016 Apr 15
TI  - Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with 
      Stable Coronary Artery Disease: A Cross-Sectional Study.
PG  - 454
LID - 10.3390/ijms17040454 [doi]
LID - 454
AB  - A recent experimental study suggested that proton pump inhibitors (PPI), widely 
      used to prevent gastroduodenal complications of dual antiplatelet therapy, may 
      increase the accumulation of the endogenous nitric oxide synthesis antagonist 
      asymmetric dimethylarginine (ADMA), an adverse outcome predictor. Our aim was to 
      assess the effect of PPI usage on circulating ADMA in coronary artery disease 
      (CAD). Plasma ADMA levels were compared according to PPI use for >/=1 month prior 
      to admission in 128 previously described non-diabetic men with stable CAD who 
      were free of heart failure or other coexistent diseases. Patients on PPI tended 
      to be older and with insignificantly lower estimated glomerular filtration rate 
      (GFR). PPI use was not associated with any effect on plasma ADMA (0.51 +/- 0.11 
      (SD) vs. 0.50 +/- 0.10 micromol/L for those with PPI (n = 53) and without PPI (n = 75), 
      respectively; p = 0.7). Additionally, plasma ADMA did not differ between PPI 
      users and non-users stratified by a history of current smoking, CAD severity or 
      extent. The adjustment for patients' age and GFR did not substantially change the 
      results. Thus, PPI usage does not appear to affect circulating ADMA in 
      non-diabetic men with stable CAD. Whether novel mechanisms of adverse PPI effects 
      on the vasculature can be translated into clinical conditions, requires further 
      studies.
FAU - Kruszelnicka, Olga
AU  - Kruszelnicka O
AD  - Department of Coronary Artery Disease and Heart Failure, Jagiellonian University 
      Medical College and John Paul II Hospital, 80 Pradnicka, 31-202 Cracow, Poland. 
      olga.kruszelnicka@onet.pl.
FAU - Swierszcz, Jolanta
AU  - Swierszcz J
AD  - Second Department of Cardiology, Jagiellonian University Medical College and 
      University Hospital, 17 Kopernika, 31-501 Cracow, Poland. 
      grasshoppers@interia.eu.
FAU - Bednarek, Jacek
AU  - Bednarek J
AD  - Department of Electrocardiology, John Paul II Hospital, 80 Pradnicka, 31-202 
      Cracow, Poland. bednareks@op.pl.
FAU - Chyrchel, Bernadeta
AU  - Chyrchel B
AD  - Second Department of Cardiology, Jagiellonian University Medical College and 
      University Hospital, 17 Kopernika, 31-501 Cracow, Poland. chyrchelb@gmail.com.
FAU - Surdacki, Andrzej
AU  - Surdacki A
AD  - Second Department of Cardiology, Jagiellonian University Medical College and 
      University Hospital, 17 Kopernika, 31-501 Cracow, Poland. 
      surdacki.andreas@gmx.net.
FAU - Nessler, Jadwiga
AU  - Nessler J
AD  - Department of Coronary Artery Disease and Heart Failure, Jagiellonian University 
      Medical College and John Paul II Hospital, 80 Pradnicka, 31-202 Cracow, Poland. 
      jnessler@interia.pl.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160415
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - 63CV1GEK3Y (N,N-dimethylarginine)
RN  - 94ZLA3W45F (Arginine)
RN  - D8TST4O562 (Pantoprazole)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/adverse effects
MH  - Aged
MH  - Arginine/*analogs & derivatives/blood
MH  - Coronary Artery Disease/*blood/complications
MH  - Cross-Sectional Studies
MH  - Dose-Response Relationship, Drug
MH  - Glomerular Filtration Rate/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Omeprazole/administration & dosage/adverse effects
MH  - Pantoprazole
MH  - Peptic Ulcer/*prevention & control
MH  - Proton Pump Inhibitors/*administration & dosage/adverse effects
MH  - Treatment Outcome
PMC - PMC4848910
OTO - NOTNLM
OT  - asymmetric dimethylarginine
OT  - coronary artery disease
OT  - proton pump inhibitors
EDAT- 2016/04/20 06:00
MHDA- 2016/12/17 06:00
PMCR- 2016/04/01
CRDT- 2016/04/20 06:00
PHST- 2016/01/30 00:00 [received]
PHST- 2016/03/07 00:00 [revised]
PHST- 2016/03/22 00:00 [accepted]
PHST- 2016/04/20 06:00 [entrez]
PHST- 2016/04/20 06:00 [pubmed]
PHST- 2016/12/17 06:00 [medline]
PHST- 2016/04/01 00:00 [pmc-release]
AID - ijms17040454 [pii]
AID - ijms-17-00454 [pii]
AID - 10.3390/ijms17040454 [doi]
PST - epublish
SO  - Int J Mol Sci. 2016 Apr 15;17(4):454. doi: 10.3390/ijms17040454.